Diagnosis of communicable and non-communicable diseases and their treatment in humans, animals, and agriculture are the largest challenge in the 21st Century. Bangladesh Biosafety and Biosecurity Society (BBBS) is planning to organize the 2025 Annual Biorisk Conference at the Rangamati Science and Technology University on 16 to 17 May 2025. Academics, Scientists, Researchers, Policymakers, and other relevant scholars are invited to participate in the BBBS annual conference and submit abstracts* until 15th April 2025, focusing on diagnosis, treatment, prevention, control and eradication of infectious diseases, and more. Abstracts accepted selected for oral presentation should be in any of the areas mentioned above, or on other infectious diseases or related issues, as a potential threat to Bangladesh and its neighboring countries.

Day 1: Friday, May 16, 2025

Opening Ceremony

14:31 – 14:35  Welcome Address by Honorable Vice-Chancellor, Rangamati Science and Technology University and the Conference Chair

14:36 – 15:50  Plenary Lectures 1, 2, and 3

15:51 – 15:55  Address by Special Guest 1

15:56– 16:00   Address by Special Guest 2

16:01 – 16:05  Address by Chief Guests 

16:06 – 16:10  Vote of Thanks by General Secretary, BBBS

16:11 – 16:30  Tea break

Technical Sessions

16:31 – 17:40   Technical Session 1 - Current Challenges in the Control and Eradication of Emerging and Reemerging Infectious Diseases in Humans

Control and eradication of emerging and reemerging infectious diseases depends on biological, environmental, and physical control measures. Availability of vaccines, vaccine hesitancy, and vaccine efficacy are the important factors to discuss under the biological control measures. Strategies, policies, procedures and guidelines are also expected to be discussed during the session on controlling the environmental spread of the diseases. Biorisk management program for laboratories dealing with biohazardous materials, and overall biorisk management in clinical care would be most expected topics to be discussed in this session. 

17:00 – 18:00   Poster Session

17:41 – 20:00  Prayer, Afternoon Tea, Site Seeing and Gala Dinner

Day 2: Saturday, May 17, 2025

09:00 – 10:30  Technical Session 2A - Diagnosis and Treatment of Emerging and Reemerging Infectious Disease in Animals and Agriculture

Most of the human infectious diseases are zoonotic. Major animal diseases like: Bluetongue, Avian Influenza, African Swine Fever, Peste des petits ruminants, Canine Influenza, Canine distemper, Chronic Wasting Disease, and Anthrax are circulating in the world. Public awareness is necessary to deal with more serious issues connected to the threat posed by emerging and reemerging phytopathogens to food crops, forest trees, and other ecosystem services provided by the environment. Pathogen distribution and climate interactions, relationships between pathogenic virulence and climate, and the effect of climate on emerging pathogens are highly welcome to be discussed. Recent development in the field of GMO and LMO in the country and worldwide can also be highlighted.

09:00 – 10:30  Technical Session 2B - Drug Discovery and Development

The process of finding novel drugs to treat different illnesses is called drug discovery. Target identification, lead discovery, lead optimization, preclinical testing, clinical trials, and regulatory approval are some of the phases in this lengthy and complex process. A drug can take between ten and fifteen years to move from clinic to approval, versus the a few weeks or less needed for being useless for the treatment of infections. This has become a great challenge for treating infectious disease. Drug research and discovery depend heavily on clinical trials. They are intended to assess a possible new drug’s pharmacokinetics, effectiveness, and safety in human subjects. Each step of clinical trials is intended to address a particular query concerning the safety and effectiveness of the medicine. The results of clinical studies are used to assess a drug’s efficacy and safety, as well as its suitability for patient marketing. Even once a medicine is licensed, ongoing monitoring is necessary to guarantee its efficacy and safety. Recent development in the area Drug Discovery and Development, at home and abroad, is expected to be discussed during this session.

10:31 – 10:00  Tea break

11:01 – 12:30  Technical Session 3A - Containment of Antimicrobial Resistance:

One Health and Containment of Antimicrobial Resistance Infectious diseases were the leading cause of morbidity and mortality. Antimicrobials have been hugely successful in improving health outcomes. The annual mortality rate due to infectious diseases was rapidly decreasing, by 8.2% per year, and this decline corresponded to the introduction into clinical practice of antimicrobial agents since 1935. The positive impact of antibiotics on health, however, is threatened by increasing levels of AMR worldwide and hampered by the lack of access to essential antibiotics in many low-income and middle-income countries. Abstracts are invited to discuss policies, procedures, strategies, and research and recent development towards the containment of AMR.

11:01 – 12:30  Technical Session 3B - Alternative medicine and natural products in human animal and environmental health

The objective of medicine is to address people’s unavoidable needs for emotional and physical healing. The discipline has evolved over millennia by drawing on the religious beliefs and social structures of numerous indigenous peoples, by exploiting natural products in their environments, and more recently by developing and validating therapeutic and preventive approaches using the scientific method. Public health and medical practices have now advanced to a point at which people can anticipate - and even feel entitled to - lives that are longer and of better quality than ever before in human history. The lack of product quality and consistency and the absence of compelling data on the safety and efficacy of most Complementary and Alternative Medicine (CAM) and traditional medicine (TM) approaches present major challenges to any effort to optimize the distribution of precious health resources. Recent development in the area CAM and TM, at home and abroad, is expected to be discussed during this session.

12:00 – 13:00   Poster Session

12:31 – 14:00  Lunch Break

14:01 – 15:30  Interdisciplinary and Institutional Regulatory Framework:

Establishing interdisciplinary and Regulatory Framework require inter-organizational collaboration to work together avoiding duplication of efforts following national and international guidelines and standards. In this session, it is expected that Academics, Scientists, Administrators, and Policymakers will discuss on the current guidelines and standards and the implementation plan of respective Ministries and Departments. Academics and researchers are also expected to discuss institutional strategies for implementation of biorisk management programs with the aim of developing preparedness for a future pandemic

15:31 – 15:40  Closing of Technical Sessions, President BBBS

15:41 – 16:00  Afternoon Tea

Day 3: Sunday, May 18, 2025

Carnival

Conference Registration || Bangladesh Biosafety and Biosecurity Society (bd-biosafetysecurity.org)

*Submitted abstracts accepted but not selected for oral presentation will be published in the E-book to be available online on the BBBS webpage.

Guidelines for Submission of Abstract

Each registrant may submit one abstract of his or her presentation during the conference. Please take note that all abstracts will be reviewed by the scientific committee. They will decide on the final acceptance for presentation for each abstract. All registrants will be advised accordingly by 20th April 2025. Selected abstracts will ONLY be accepted upon receipt of registration and payment for the conference fee.

Abstracts

1.   All abstracts must be in ENGLISH, the combined length of the abstract title, list of authors, and body should not exceed 300 words. Please be sure to carefully check your abstract for content errors, spelling, names, etc. before submitting. BBBS does not proofread for correct spelling, typographical, grammatical, or scientific errors, nor can changes be made once the abstract is submitted.

2.   Title should be brief, in bold capital letters at the top of the abstract.

3.   Author(s) should be listed by surname (underline) and initials, with the presenting author’s name underlined. The designation and organization should immediately follow the authors’ names. (Organization/Institute, department, city, state, country of author).

4.   Text must be typed single-spaced, font 12 Arial with only the left margin justified.

5.   Leave one line between the title/author/institution and the body of the abstract.

6.   Each abstract should contain: (a) an introductory sentence indicating the objective of the abstract (b) main content, including methods and results if relevant and (c) conclusions. It is expected that the abstract will include the summary of the original presentation.

7.   Graphs, tables and illustration cannot be included in the abstract.

8.   The abstract document MUST BE in PDF/WORD.doc format. Any other file type WILL NOT be accepted.

9.   Abstracts must be submitted by abstract submission portal as Microsoft Word attachment.

*Submitted abstracts accepted but not selected for oral presentation will be published in the E-book to be available online on the BBBS webpage.

Annual Conference 2025 of the Society is going to be organized on 16 - 17 May 2025. Participants from all over Bagladesh and other countries working in the following disciplines are invited to participate in this conference.

• Agriculturalist, Biochemist, Biotechnologists, Botanists, Clinical Biochemists, Clinical Microbiologists, Clinical Pathologists, Environmentalists, Medical Doctors, Medical Microbiologists, Medical Technologists, Microbiologists, Molecular Biologists, Veterinarians, and Zoologists including all the disciplines of Biological Sciences
• Biosafety Professionals and Practitioners
• Biosafety Managers
• Consultants in relevant areas
• Engineers and Architects working for designing hospitals, laboratories, or related facilities
• Professionals interested in the updates on Biosafety and Biosecurity
• Scientists, Researchers and Laboratory Workers